Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVATAK Extension in Advanced Melanoma
NCT01636882Phase 2Completed
- Sponsor
- Viralytics Ltd
- Start
- Jul 2012
- Primary completion
- Apr 2016
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coxsackievirus a21 in melanoma, sponsored by Viralytics Ltd. Primary endpoint: Safety at 12 months. Started Jul 2012; status: completed.
02
Drugs
coxsackievirus a21
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01636882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636882.